6-bromo-3-hydroxypyrazine-2-carboxamide is used to prepare viral polymerase inhibitor T-705 to prevent Zika virus replication.
Favipiravir, also known as T-705 or Avigan, is an antiviral drug being developed by Toyama Chemical (Fujifilm group) of Japan with activity against many RNA viruses. In February 2020 Favipiravir was being studied in China for experimental treatment of the emergent COVID-19 (novel coronavirus) disease and it has show positive results.
4-dihydro-pyrazine-2-carboxylic acid amide.
|Appearance||Yellowish to off – white crystalline powder||Purity||98%|
For research use only
|COA & NMR||Download||MSDS||Download|
 Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. (2020-03-18). “Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study”. Engineering. doi:10.1016/j.eng.2020.03.007. ISSN 2095-8099.
 Murphy J, Sifri CD, Pruitt R, Hornberger M, Bonds D, Blanton J, et al. (January 2019). “Human Rabies – Virginia, 2017”. MMWR. Morbidity and Mortality Weekly Report. 67 (5152): 1410–1414.
 EJ Lane (June 22, 2016). “Fujifilm in Avigan API license with Zhejiang Hisun Pharmaceuticals”. Fierce Pharma. Retrieved April 20, 2020.
 “MediVector Completes Patient Enrollment In Two Phase 3 Studies Of Favipiravir For Influenza”. BioSpace. Retrieved 5 May 2020.